# Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan

> **NCT02977312** · — · COMPLETED · sponsor: **Hikma Pharmaceuticals LLC** · enrollment: 91 (actual)

## Conditions studied

- Chronic Myeloid Leukemia, Chronic Phase

## Interventions

- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT02977312
- **Lead sponsor:** Hikma Pharmaceuticals LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2016-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02977312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02977312, "Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02977312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*